Liver Cancer (HCC) Treatment in Lucknow
Expert HCC at Lucknow Cancer Institute
Hepatocellular carcinoma (HCC), commonly called primary liver cancer, usually develops in people who already have liver damage such as cirrhosis or chronic hepatitis B/C infection. It is one of the fastest‑growing cancers worldwide and often gets detected late because early symptoms are very mild or absent. At Lucknow Cancer Institute, Dr. Sidharth Pant provides comprehensive liver cancer care, including evaluation of underlying liver disease, staging, systemic therapy (targeted therapy and immunotherapy), and close coordination with liver surgeons and interventional radiologists.
Hepatocellular Carcinoma: Global & India Data
Understanding the worldwide and Indian burden of liver cancer
Global Burden
- HCC is the sixth most common cancer and the third leading cause of cancer‑related death worldwide
- An estimated 900,000–1,000,000 new cases and over 800,000 deaths occur each year globally
- Age‑standardized incidence is around 10 per 100,000, with highest rates in East Asia and sub‑Saharan Africa
- Major global risk factors: chronic hepatitis B virus (HBV), hepatitis C virus (HCV), alcohol‑related liver disease, and MASLD/NAFLD
- With HBV vaccination and modern antivirals, viral‑related HCC is declining in some regions
- MASLD‑ and alcohol‑related HCC are rising globally
India Epidemiology
- Current HCC incidence in India is about 2.15 per 100,000, lower than global average but increasing steadily
- National cancer registry data show 11% relative increase in incidence between 2004 and 2014
- Males are more affected than females, with male‑to‑female ratio around 4:1
- Most patients present between 40–70 years of age
- Northeastern states like Kamrup (Assam) show highest incidence (up to 6.2 per 100,000)
- Western states (Gujarat, Maharashtra, Goa, Kerala) are emerging hotspots
- Etiologic pattern shifting: HBV‑related HCC declining, alcohol and MASLD becoming leading causes
Risk Factors & Prevention
Understanding and preventing hepatocellular carcinoma
Major Risk Factors
Viral Hepatitis:
- Chronic Hepatitis B: Main driver of HCC in high‑incidence regions; risk persists even after viral suppression
- Chronic Hepatitis C: Long‑standing HCV infection leads to cirrhosis and significantly raises HCC risk
Liver Conditions:
- Cirrhosis: Single most important background for HCC development from any cause
- MASLD/NAFLD: Rapidly growing cause worldwide and increasingly important in India
- Alcohol‑Related Liver Disease: Heavy, long‑term alcohol intake accelerates cirrhosis and HCC risk
Prevention Strategies
Primary Prevention:
- Universal HBV vaccination for all newborns and high-risk adults
- Timely antiviral therapy for HBV/HCV infections
- Early diagnosis and management of fatty liver, obesity, and diabetes
- Alcohol use reduction and cessation programs
- Safe food storage to prevent aflatoxin contamination
Secondary Prevention:
- Regular surveillance in cirrhotics to detect HCC at curable stage
- 6‑monthly ultrasound with/without AFP for high-risk patients
- Early intervention for detected lesions
Symptoms & When to Suspect HCC
Recognizing warning signs of hepatocellular carcinoma
Common Symptoms
Many patients with HCC are asymptomatic in early stages, especially if they are on routine surveillance for chronic liver disease. Symptoms often appear when the tumour is large or liver function is compromised.
Abdominal Pain
Dull pain or discomfort in right upper abdomen
Weight Loss
Unexplained weight loss and loss of appetite
Fatigue
Persistent fatigue and general weakness
Abdominal Swelling
Ascites (fluid accumulation in abdomen)
Jaundice
Yellowing of skin and eyes
Bleeding Issues
Easy bruising or bleeding (advanced liver disease)
Alarm Signs in Patients with Known Cirrhosis
- Sudden worsening of liver function
- New‑onset or rapidly increasing ascites
- Unexplained fever, weight loss, or decline in health
- Any new symptoms in patients with chronic liver disease require immediate evaluation
Diagnosis & Staging
Comprehensive diagnostic approach and staging systems for HCC
Screening & Diagnostic Work-Up
Surveillance
High‑risk patients (cirrhosis, chronic HBV/HCV, advanced MASLD) should undergo ultrasound liver with/without AFP every 6 months
Blood Tests
Liver function tests, coagulation profile, viral markers (HBV/HCV), AFP (alpha‑fetoprotein)
Imaging
Triphasic contrast‑enhanced CT or MRI liver to identify classic arterial enhancement and venous washout pattern
Biopsy
May be avoided when imaging is characteristic in cirrhotic liver; used when diagnosis is uncertain
Key Point
Surveillance helps detect small, potentially curable tumours (≤2 cm). Early detection through regular screening significantly improves treatment outcomes and survival rates.
BCLC Staging System
BCLC Staging
BCLC (Barcelona Clinic Liver Cancer) staging is widely used because it incorporates tumour burden, liver function, and performance status to guide treatment decisions and predict prognosis.
Treatment Options
Comprehensive treatment approaches for hepatocellular carcinoma
Curative Treatments
- Surgical Resection: For patients with preserved liver function and limited tumour
- Liver Transplantation: Ideal for patients meeting Milan criteria
- Local Ablation (RFA/MWA): For small tumours (≤3 cm) when surgery not feasible
Locoregional Treatments
- Transarterial Chemoembolization (TACE): For intermediate‑stage HCC
- Transarterial Radioembolization (TARE/Y‑90): For selected cases with portal vein thrombosis
- Stereotactic Body Radiotherapy (SBRT): For unresectable or oligofocal disease
Systemic Therapy
- First‑line: Atezolizumab + bevacizumab, Durvalumab + tremelimumab
- Tyrosine Kinase Inhibitors: Sorafenib, lenvatinib, regorafenib, cabozantinib
- Second‑line: Other TKIs and immunotherapies based on prior treatment
Supportive & Palliative Care
- Management of pain, ascites, encephalopathy
- Nutritional support and symptom control
- Psychological support for patients and families
- Quality of life optimization
HCC in India: Key Challenges
Addressing the growing burden of liver cancer in India
Major Challenges
Rising Burden
Driven by MASLD, alcohol, and still‑significant viral hepatitis
Late Presentation
Due to lack of systematic surveillance for cirrhosis
Limited Access
To transplant and advanced locoregional therapies in some regions
Awareness Gap
Limited public awareness about liver cancer prevention
Priority Areas for Action
Primary Prevention:
- Scaling up HBV vaccination coverage
- Timely antiviral therapy for HBV/HCV
- Public health action on obesity, diabetes, and alcohol use
Secondary Prevention:
- Establishing robust cirrhosis/HCC surveillance programs
- Training healthcare providers in early detection
- Improving access to diagnostic facilities